Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Immunotherapy targeting α-synuclein protofibrils reduced pathology in (Thy-1)-h[A30P] α-synuclein mice.

Neurobiology of disease - 1 Sept 2014

Lindström Veronica, Fagerqvist Therese, Nordström Eva, Eriksson Fredrik, Lord Anna, Tucker Stina, Andersson Jessica, Johannesson Malin, Schell Heinrich, Kahle Philipp J, Möller Christer, Gellerfors Pär, Bergström Joakim, Lannfelt Lars, Ingelsson Martin

Abstract excerpt

Several lines of evidence suggest that accumulation of aggregated alpha-synuclein (α-synuclein) in the central nervous system (CNS) is an early pathogenic event in Parkinson's disease and other Lewy body disorders. In recent years, animal studies have indicated immunotherapy with antibodies directed against α-synuclein as a promising novel treatment strategy. Since large α-synuclein oligomers, or protofibrils,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to alpha-Synuclein
Share to Antibodies, Monoclonal

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Enzyme-Linked Immunosorbent Assay

Share to Immunization, Passive

Share to Injections, Intraperitoneal

Share to Motor Activity

Share to Parkinsonian Disorders

Share to Spinal Cord

Source

Identifiers

PMID: 24851801
DOI: 10.1016/j.nbd.2014.05.009

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Immunotherapy targeting α-synuclein protofibrils reduced pathology in (Thy-1)-h[A30P] α-synuclein mice.PMID 24851801Read ↗

Monoclonal antibodies selective for α-synuclein oligomers/protofibrils recognize brain pathology in Lewy body disorders and α-synuclein transgenic mice with the disease-causing A30P mutation.Semantic proximity Read ↗

Transgenic Models of α‐Synuclein PathologySemantic proximity Read ↗

AAV-mediated Expression of a Novel Conformational Anti-Aggregated α-Synuclein Antibody Prolongs Survival in a Genetic Model of α-SynucleinopathiesSemantic proximity Read ↗

Development of an α-synuclein knockdown peptide and evaluation of its efficacy in Parkinson's disease models.Semantic proximity Read ↗

Molecular properties and diagnostic potential of monoclonal antibodies targeting cytotoxic α-synuclein oligomersSemantic proximity Read ↗

Neurotoxic conversion of beta-synuclein: a novel approach to generate a transgenic mouse model of synucleinopathies?Semantic proximity Read ↗

Monoclonal antibodies targeting cytotoxic α-synuclein oligomers: molecular properties and diagnostic potentialSemantic proximity Read ↗

Increased Oxidative Stress Exacerbates α-Synuclein Aggregation In VivoSemantic proximity Read ↗

Hsp70 Reduces α-Synuclein Aggregation and ToxicitySemantic proximity Read ↗

Telomere shortening leads to an acceleration of synucleinopathy and impaired microglia response in a genetic mouse model.Semantic proximity Read ↗

Inhibiting Aggregation of α-Synuclein with Human Single Chain Antibody FragmentsSemantic proximity Read ↗

Protective effect of TAT-delivered alpha-synuclein: relevance of the C-terminal domain and involvement of HSP70.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.